Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOT-12 adjuvant bempegaldesleukin plus nivolumab versus nivolumab in resected high-risk melanoma
2020-000917-34Phase 3Completed
- Sponsor
- Nektar Therapeutics
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma and cutaneous melanoma (CM) comparing Bempegaldesleukin plus nivolumab with Nivolumab (2 arms). Primary endpoint: Recurrence-free survival by blinded independent central review. Started Jul 2020; status: completed.
02
Drugs
bempegaldesleukinnivolumab
03
Conditions
melanomacutaneous melanoma (CM)
Beyond the preview
Go deeper on 2020-000917-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000917-34.